ORIGINAL ARTICLE [OPEN ACCESS](https://doi.org/10.1111/crj.70038)

Causal Association Between Monounsaturated Fatty Acids and Lung Cancer: A Two-Sample Mendelian Randomization Study

Shaofeng Zhang^{[1](#page-0-0)} | Jia Jiang¹ | Xiping Wu^{[2](#page-0-1)} | Jiayi Liu¹ | Wei Lei¹ | Sigin Chen¹ | Yaling Zeng¹ | Xiang Liu^{[3](#page-0-2)} | Oiang Xiao¹

¹Pulmonary and Critical Care Medicine, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde, Foshan), Foshan, Guangdong, China | 2Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China | 3Departments of Hematology, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde, Foshan), Foshan, Guangdong, China

Correspondence: Xiang Liu (angu870751@163.com) | Qiang Xiao [\(xiaoqiang@smu.edu.cn\)](mailto:xiaoqiang@smu.edu.cn)

Received: 30 June 2024 | **Revised:** 4 November 2024 | **Accepted:** 20 November 2024

Funding: This work was supported by the Guangdong Basic and Applied Basic Research Foundation (2020A1515110973) and the China Postdoctoral Science Foundation (2020M670014ZX).

Keywords: causality | lung cancer | Mendelian randomization | monounsaturated fatty acids

ABSTRACT

Objective: This study aims to investigate the potential causal relationship between monounsaturated fatty acids (MUFAs) and lung cancer.

Methods: Genetic data on MUFAs and pathological subtypes of lung cancer were extracted from genome-wide association studies (GWAS). The primary analysis utilized inverse-variance weighted analysis (IVW), with additional methods including the weighted median method, MR-Egger regression method, and weighted model method. Sensitivity analysis was conducted to assess the robustness of the findings.

Results: The inverse variance–weighted (IVW) analysis of monounsaturated fatty acids in relation to lung adenocarcinoma yielded an odds ratio (OR) of 1.059 with a 95% confidence interval of 0.960 to 1.168 and a *p* value of 0.252. Similarly, for lung squamous cell carcinoma, the IVW analysis produced odd ratios of 0.884, 95% confidence intervals of 0.747 to 1.045, and a *p* value of 0.148. In the case of small cell lung cancer, the odds ratio was 0.936, the 95% confidence interval was 0.751 to 1.166, and the *p* value was 0.554.

Conclusion: It can be concluded that there is no direct causal relationship between monounsaturated fatty acids and the development of lung cancer.

1 | Introduction

Lung cancer is a prevalent malignant neoplasm worldwide, ranking second in global incidence rates of malignancies and serving as a leading cause of cancer-related mortality [\[1, 2\]](#page-6-0). The escalating trend in diagnosis rates underscores the significance of lung cancer as a pressing public health concern in China, where its increasing morbidity and mortality rates impose a substantial burden on society [[3\]](#page-6-1). Based on various pathological classifications, lung cancer can be categorized into non–small cell lung cancer, which accounts for 85% of total diagnoses, and small cell lung cancer, which accounts for 15% of total diagnoses. Among non–small cell lung cancer cases, adenocarcinoma is the most prevalent type, followed by squamous cell carcinoma

Shaofeng Zhang, Jia Jiang, and Xiping Wu contributed equally to this work.

This is an open access article under the terms of the [Creative Commons Attribution](http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2024 The Author(s). The Clinical Respiratory Journal published by John Wiley & Sons Ltd.

[\[4](#page-6-2)]. Given the significant prevalence and mortality rates associated with lung cancer, it is crucial to conduct screenings for unidentified risk factors, such as dietary habits.

Monounsaturated fatty acids (MUFAs) are a type of fatty acid characterized by the presence of a double bond in their chemical structure, with prominent examples including oleic acid (OA) and palmitoleic acid (PA). These fatty acids are commonly found in various dietary sources. Research has demonstrated that single unsaturated fatty acids can potentially contribute to the prevention and treatment of type 2 diabetes and reduction of cardiovascular disease [\[5, 6](#page-6-3)]. However, their susceptibility to oxidation in the body, leading to the generation of superoxide, poses a potential safety hazard and risk of adverse reactions. Palmitoleic acid, for instance, can enhance insulin sensitivity and reduce fat accumulation, showing anti-inflammatory effects. MUFAs are considered beneficial for cardiovascular health and may lower the risk of atherosclerosis [[7\]](#page-6-4).

In studies examining the relationship between monounsaturated fatty acids and cancer, it was observed that olive oil, which is rich in oleic acid, plays a modulating role in cancer development [\[8](#page-6-5)]. The exogenous introduction of monounsaturated fatty acids or the upregulation of stearoyl-CoA desaturase 1 (SCD1) results in an increase in endogenous monounsaturated fatty acids, thereby enhancing the ability of ovarian cancer cells to withstand ferroptosis and ultimately promoting cancer progression [\[9\]](#page-6-6). Polyunsaturated fatty acids (PUFAs) are characterized by the presence of two or more double bonds. Research indicates a potential link between a high consumption of polyunsaturated fatty acids and a decreased risk of lung cancer, whereas the association between MUFAs and lung cancer risk remains inconclusive [\[10](#page-6-7)]. Furthermore, observational studies may be influenced by various confounding variables, and the direct causal relationship between monounsaturated fatty acids and lung cancer risk requires further investigation.

The Mendelian randomization study (MR) utilizes instrumental variables, specifically the genetic variation of single nucleotide polymorphisms (SNPs), to investigate factors that influence outcome variables. By employing SNPs as genetic factors, this approach mitigates biases stemming from environmental, investigator, behavioral, and social factors typically present in observational studies. Furthermore, Mendelian research provides a clear and unidirectional assessment of causality, less susceptible to the confounding effects of reverse causation.

Previous research has indicated a potential correlation between lung cancer and monounsaturated fatty acids, although these findings may be influenced by confounding variables or the potential for reverse causation. This study employs Mendelian randomization methods to investigate the direct causal relationship between three pathological types of lung cancer, monounsaturated fatty acids, and lung cancer.

2 | Materials and Methods

2.1 | Selection of Genetic Variants

This study utilized MUFAs as the exposures of interest and identified significant MUFAs SNPs as instrumental variables. The findings indicated a relationship with lung cancer through Mendelian randomization analysis. Heterogeneity was assessed using Cochran's *Q* test, and sensitivity analysis was conducted using the MR-Egger intercept and one method.

The study design depicted in Figure [1](#page-1-0) is grounded in the fundamental principles of Mendelian randomization methods and must adhere to the following three hypotheses [\[11](#page-6-8)]: (1) The instrumental variable must have a direct relationship with the exposure factors; (2) the instrumental variable should not be influenced by external confounding factors; (3) the instrumental variable must solely impact outcome factors through exposure factors.

2.2 | Data Sources

MUFAs and lung cancer data were obtained from the GWAS database [\(https://gwas.mrcieu.ac.uk/\)](https://gwas.mrcieu.ac.uk/), utilizing data sourced from publicly available research papers [\[12\]](#page-6-9). The original

Exclusive hypothesis

FIGURE 1 | Study design.

ethical approval documentation for this study has been acquired, and no further ethical review is deemed necessary. Specific data details can be found in Table [1](#page-2-0). The analysis of over 110 000 samples provided data on MUFAs, whereas information on lung cancer was obtained through genotyping of 14 803 European patients with lung cancer and 12 262 controls, as well as genome-wide association studies (GWAS) involving 29 266 patients and 56 450 controls across three distinct pathological types of lung cancer.

2.3 | Study Methods

2.3.1 | Screening of Instrumental Variables

The instrumental variables selected must adhere to the criterion of being associated with exposure factors, with a screening threshold set at *p* < 5×10[−]8. Additionally, these SNPs must satisfy linkage disequilibrium (LD) conditions of r^2 < 0.001 and kb > 10 000 to ensure their validity. Following screening, SNPs directly linked to outcome factors were excluded, whereas those associated with outcome factors were retained. Allele data for both exposure and outcome factors were harmonized, and palindromic SNPs were eliminated. The remaining SNPs were utilized in the subsequent Mendelian randomization analysis.

2.4 | MR Analysis

The "Two Sample MR" package within R software version 4.3.1 was utilized for conducting MR analysis, primarily employing the inverse variance weighting method, along with supplementary methods such as MR-Egger regression, weighted median, and weighted mode. Heterogeneity was assessed using the Cochran *Q* test, with the inverse variance weighted random effects model applied for $P \geq 0.05$, and the inverse variance weighted fixed effects model utilized for $p < 0.05$.

2.5 | Sensitivity Analysis

The MR-Egger regression method was employed to assess pleiotropy. An MR-Egger regression intercept with a *p* value greater than 0.05 suggests the absence of horizontal pleiotropy. The leave-one-out test was utilized to evaluate the impact of individual SNPs on outcome variables. In cases where a SNP demonstrated a significant effect, it was removed from the analysis and the MR analysis was repeated.

3 | Results

3.1 | Causal Relationship Between MUFAs and Lung Adenocarcinoma

Instrumental variables: According to the principle of "Screening of instrumental Variables" in this paper, 51 SNPs were finally included for subsequent Mendelian randomization analysis.

The MR analysis and sensitivity analysis utilized the Cochran *Q* test, which yielded a *p* value of 0.3844. The random effect model using the inverse variance weighting method was selected with a *p* value of 0.252. Additionally, the MR-Egger regression method, weighted median method, and weighted pattern method all produced results consistent with the inverse variance weighting method, with all *p* values exceeding 0.05. The results of the inverse variance–weighted (IVW) analysis yielded an odds ratio (OR) of 1.059 with a 95% confidence interval (CI) of 0.960 to 1.168, as depicted in Figure [2A,](#page-3-0) Figure [3A](#page-3-1), and Table [2A.](#page-4-0) The MR Egger regression intercept *p* value of 0.777 suggests the absence of horizontal pleiotropy. Sensitivity analyses utilizing the leave-one-out method (Figure [4A](#page-4-1)) demonstrated no significant impact of individual SNPs on the outcomes. Consequently, it can be inferred that MUFAs do not exert a causal influence on the development of lung adenocarcinoma.

3.2 | Causal Relationship Between MUFAs and Lung Squamous Cell Carcinoma

Instrumental variables: According to the principle of "Screening of instrumental Variables" in this paper, 54 SNPs were finally included for subsequent Mendelian randomization analysis.

The MR analysis and sensitivity analysis employed the Cochran's Q test, which resulted in a *p* value of 0.00005558. The inverse variance weighting method with a random effects model was chosen, yielding a *p* value of 0.148. Furthermore, the MR-Egger regression, weighted median, and weighted pattern methods all provided results consistent with the inverse variance weighting method, with all *p* values exceeding 0.05. The result of the IVW analysis was OR=0.884, 95% CI (0.747~1.045) (Figure [2B,](#page-3-0) Figure [3B](#page-3-1), Table [2B](#page-4-0)). The MR-Egger regression

FIGURE 2 | Three types of lung cancer pathology Mendelian randomization forest graph of analytical results. (A) Forest plot of causal effects of SNPS associated with MUFAs on lung adenocarcinoma. The significance of the red line is the MR Results of the MR-Egger test and the IVW method. (B) Forest plot of causal effects of SNPS associated with MUFAs on lung squamous cell carcinomas. The significance of the red line is the MR Results of the MR-Egger test and the IVW method. (C) Forest plot of causal effects of SNPS associated with MUFAs on small cell lung cancer. The significance of the red line is the MR results of the MR-Egger test and the IVW method.

FIGURE 3 | Scatter plot of the results of the Mendelian randomization analysis. (A) Causal association of MUFAs on lung adenocarcinoma. (B) Causal role of MUFAs on lung squamous cell carcinoma. (C) Causal effect of MUFAs on small cell lung cancer.

intercept $p=0.858$, indicating that there was no horizontal pleiotropy. Sensitivity analyses with the leave-one-out method (Figure [4B](#page-4-1)) showed no significant effect of individual SNPs on the outcomes. Thus, there was no causal effect of MUFAs on lung squamous cell carcinoma. Sensitivity analyses utilizing the leave-one-out method (Figure [4B](#page-4-1)) revealed that individual SNPs did not have a statistically significant impact on the outcomes, indicating the absence of a causal relationship between MUFAs and lung squamous cell carcinoma.

3.3 | Causal Relationship Between MUFAs and Small Cell Lung Cancer

Instrumental variables: According to the principle of "Screening of instrumental Variables" in this paper, 51 SNPs

were finally included for subsequent Mendelian randomization analysis.

The MR analysis included sensitivity analysis using the Cochran *Q* test, which yielded a calculated *p* value of 0.004721. The inverse variance weighting method with a random effect model was selected, resulting in a *p* value of 0.554. The MR-Egger regression method, weighted median method, and weighted pattern method all showed consistency with the inverse variance weighting method, with all *p* values exceeding 0.05. The IVW analysis revealed an odds ratio of 0.936 with a 95% confidence interval of 0.751 to 1.166 (Figure [2C,](#page-3-0) Figure [3C](#page-3-1), Table [2C](#page-4-0)). The MR-Egger regression intercept yielded a *p* value of 0.975, indicating the absence of horizontal pleiotropy. Sensitivity analyses utilizing the leave-one-out method (Figure [4C](#page-4-1)) revealed that individual SNPs did not have a statistically significant impact

A. Results of Mendelian randomization analysis for lung adenocarcinoma

B. Results of Mendelian randomization analysis for lung squamous cell carcinoma

C. Results of Mendelian randomization analysis for small cell lung cancer.

Abbreviations: Beta, beta coefficient; MR, Mendelian randomization; OR, odds ratio; SE, standard error; SNP, single nucleotide polymorphism.

FIGURE 4 | Leave-one-out method for sensitivity analysis. (A) Sensitivity analysis of MUFAs for lung adenocarcinoma. (B) MUFAs sensitivity analysis for lung squamous cell carcinoma. (C) MUFAs sensitivity analysis for small cell lung cancer.

on the outcomes, indicating that MUFAs do not exhibit a causal relationship with small-cell lung cancer.

4 | Discussion

This study conducted an analysis of the causal relationship between MUFAs and lung cancer across three distinct pathological subtypes of lung cancer utilizing a two-sample Mendelian randomization approach. The results of the MR analysis indicated that there was no evidence of a direct causal association between exposure to MUFAs and the development of lung cancer.

The findings of this study suggest that the consideration of MUFAs exposure may have an indirect impact on the outcomes of lung cancer through various mechanisms [\[13\]](#page-6-10). Numerous studies have demonstrated the significant role of fatty acids in cancer development, as well as their effects on tumors, cardiovascular diseases, and inflammation, garnering considerable attention. MUFAs, including oleic acid, are essential components of dietary fat intake and cannot be synthesized by the human body, primarily sourced from certain vegetable oils as dietary supplements.

This is the first study to examine the relationship between monounsaturated fatty acids and lung cancer (especially of multiple lung cancer pathotypes) using Mendelian randomization. In this study, the direct causal relationship between fatty acids and lung cancer was not established, which aligns with the conclusions of several related studies. Among the existing studies on the relationship between fatty acids and lung cancer, PUFAs account for the majority of studies. For instance, Zhang et al. conducted a meta-analysis that found no significant link between high PUFA consumption and lung cancer risk (RR 0.91, 95% CI 0.78–1.06) [\[14\]](#page-6-11). Moreover, specific fatty acids can have varying effects across different populations. Luu et al. suggested that EPA intake might be associated with a higher lung cancer risk in female non-smokers [\[15\]](#page-6-12), indicating that the influence of various fatty acids can differ among demographic groups. Additionally, Kojima et al. reported that high levels of omega-3 PUFAs were inversely related to colorectal cancer risk, supporting potential biological mechanisms by which fatty acids may impact cancer development [\[16](#page-6-13)]. Although MUFAs do not seem to directly affect lung cancer risk, their balanced consumption in the diet remains essential. Pouchieu et al. highlighted that antioxidants could influence the carcinogenic effects of different fatty acids, underscoring the importance of interactions among dietary components [\[17\]](#page-6-14). Thus, future research should investigate the roles of specific fatty acids in various cancers and consider their interactions with other dietary elements, as recommended by Chajès et al [\[18\]](#page-6-15). In summary, these findings emphasize the need for a nuanced understanding of dietary fatty acids in cancer biology, guiding future dietary recommendations and cancer prevention strategies based on a more robust evidence base.

SCD1 plays a significant role in the conversion of saturated fatty acids to monounsaturated fatty acids, which is intricately linked to the levels of monounsaturated fatty acids. The expression of SCD1 is strongly associated with the unfavorable prognosis of lung adenocarcinoma, indicating that SCD1 may facilitate the synthesis of monounsaturated fatty acids and contribute to the poor prognosis of this cancer type [\[19](#page-6-16)]. In specific circumstances, the introduction of exogenous monounsaturated fatty acids could mitigate the deficiencies resulting from SCD1 depletion [\[20](#page-6-17)]. Moreover, polyunsaturated fatty acids play a crucial role in the process of oxidation and iron-mediated cell death, particularly in the conversion of saturated fatty acids to monounsaturated fatty acids by SCD1 [\[21\]](#page-6-18). This conversion may indirectly impact the development of lung cancer by influencing lung adenocarcinoma tolerance. Additionally, STK11 (Serine/threonine kinase 11) mutation can enhance the synthesis of monounsaturated fatty acids to inhibit ferroptosis in LUAD cells [\[22\]](#page-7-0). OA has been shown to counteract the cytotoxic effects of lung cancer–targeting drugs in cell lines with activating epidermal growth factor receptor (EGFR) mutations [\[20](#page-6-17)]; meanwhile, OA can reduce syndecan 4 expression and facilitate ferroptosis in lung cancer cells via the glutathione peroxidase 4 (GPX4)/longchain acyl-CoA synthetase (ACSL4) pathway, offering a strong rationale for employing ferroptosis-targeting drugs in lung cancer therapy [\[23](#page-7-1)]. In a separate study, the overexpression of EGFR in lung cancer cell membranes has been shown to stabilize the SCD1 protein, leading to an increase in intracellular MUFAs and promoting lung cancer growth [\[24](#page-7-2)]. Additionally, MUFAs have been found to impact the expression of programmed cell death ligand 1 (PD-L1), a crucial immune checkpoint molecule in lung cancer cells and immune cells [[25](#page-7-3)]. The regulation of immune response by MUFAs may have implications for the prognosis of lung cancer. Ultimately, MUFAs may play a role in the pathogenesis and advancement of lung cancer via an indirect mechanism, resulting in a negative clinical outcome, in accordance with the findings of the current investigation.

This study demonstrates strengths in its utilization of genetic analysis to mitigate confounding factors, such as environmental, researcher, and social influences, as well as to eliminate the impact of reverse causality. Additionally, the use of public databases with large sample sizes for subgroup analysis ensures consistency in analysis and representative data, thereby reducing deviations stemming from population heterogeneity and pathological variations. Furthermore, various statistical methods, including the inverse variance weighting method, MR-Egger regression method, weighted median method, and weighted model of comprehensive analysis, are employed to enhance the comprehensiveness and reliability of the results. The study is constrained by several limitations, including the potential introduction of confounding factors due to ineffective exclusion of weak instrumental variables in the screening process, a lack of data on the relationship between MUFAs and lung cancer in non-European populations, and the inability to conduct more detailed grouping analysis of variables such as gender, age, and smoking status due to data limitations.

5 | Conclusions

Collectively, the findings from the Mendelian randomization analysis indicate that there is no direct causal association between MUFAs and lung cancer. Nevertheless, it is possible that MUFAs may be influenced by iron levels or modulate immune responses, thereby indirectly impacting the progression of lung cancer. Further validation of these results is warranted through additional clinical and fundamental investigations.

Author Contributions

Shaofeng Zhang and Jia Jiang made substantial contributions to the conception of the work and the acquisition and analysis of data; Xiping Wu and Xiang Liu drafted the work or revised it critically for important intellectual content; Xiang Liu and Qiang Xiao approved the version to be published; Wei Lei, Siqin Chen, Yaling Zeng, and Jiayi Liu contributed significantly to the analysis and manuscript preparation.

Acknowledgments

We thank all authors who participated in this study.

Ethics Statement

The datasets were obtained from the GWAS database and all data were under ethics approval before recorded in the database.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

In this study, publicly available datasets were utilized, and the data can be accessed at the following link: <https://gwas.mrcieu.ac.uk/>.

Data Source

MUFAs and lung cancer data were obtained from the GWAS database [\(https://gwas.mrcieu.ac.uk/](https://gwas.mrcieu.ac.uk/)), utilizing data sourced from a publicly available repository of peer-reviewed research papers. The original ethical approval for this study has been obtained, rendering an additional ethical review unnecessary. Detailed information regarding the specific data can be found in Table [1](#page-2-0). The MUFAs data was analyzed from a sample size exceeding 110 000 individuals. Conversely, the data on lung cancer was gathered from genotyping of 14803 European patients with lung cancer and 12 262 controls, as well as from GWAS of 29 266 patients and 56 450 controls, categorized according to three distinct pathological types of lung cancer.

References

1. B. C. Bade and C. S. Dela Cruz, "Lung Cancer 2020: Epidemiology, Etiology, and Prevention," *Clinics in Chest Medicine* 41, no. 1 (2020): 1–24, [https://doi.org/10.1016/j.ccm.2019.10.001.](https://doi.org/10.1016/j.ccm.2019.10.001)

2. H. Sung, J. Ferlay, R. L. Siegel, et al., "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries," *CA: A Cancer Journal for Clinicians* 71, no. 3 (2021): 209–249, <https://doi.org/10.3322/caac.21660>.

3. F. Wu, L. Wang, and C. Zhou, "Lung Cancer in China: Current and Prospect," *Current Opinion in Oncology* 33, no. 1 (2021): 40–46, [https://](https://doi.org/10.1097/CCO.0000000000000703) [doi.org/10.1097/CCO.0000000000000703.](https://doi.org/10.1097/CCO.0000000000000703)

4. A. A. Thai, B. J. Solomon, L. V. Sequist, J. F. Gainor, and R. S. Heist, "Lung Cancer," *Lancet* 398, no. 10299 (2021): 535–554, [https://doi.org/](https://doi.org/10.1016/S0140-6736(21)00312-3) [10.1016/S0140-6736\(21\)00312-3](https://doi.org/10.1016/S0140-6736(21)00312-3).

5. M. Brentnall, L. Rodriguez-Menocal, R. L. De Guevara, E. Cepero, and L. H. Boise, "Caspase-9, Caspase-3 and Caspase-7 Have Distinct Roles During Intrinsic Apoptosis," *BMC Cell Biology* 14 (2013): 32, <https://doi.org/10.1186/1471-2121-14-32>.

6. R. J. Steele, A. M. Thompson, P. A. Hall, and D. P. Lane, "The p53 Tumour Suppressor Gene," *British Journal of Surgery* 85, no. 11 (1998): 1460–1467, <https://doi.org/10.1046/j.1365-2168.1998.00910.x>.

7. L. M. T. Dicks, "How Important Are Fatty Acids in Human Health and Can They Be Used in Treating Diseases?," *Gut Microbes* 16, no. 1 (2024): 2420765, [https://doi.org/10.1080/19490976.2024.2420765.](https://doi.org/10.1080/19490976.2024.2420765)

8. Z. Guo, K. F. Bergeron, M. Lingrand, and C. Mounier, "Unveiling the MUFA-Cancer Connection: Insights From Endogenous and Exogenous Perspectives," *International Journal of Molecular Sciences* 24, no. 12 (2023): 9921,<https://doi.org/10.3390/ijms24129921>.

9. L. Tesfay, B. T. Paul, A. Konstorum, et al., "Stearoyl-CoA Desaturase 1 Protects Ovarian Cancer Cells From Ferroptotic Cell Death," *Cancer Research* 79, no. 20 (2019): 5355–5366, [https://doi.org/10.1158/0008-](https://doi.org/10.1158/0008-5472.CAN-19-0369) [5472.CAN-19-0369](https://doi.org/10.1158/0008-5472.CAN-19-0369).

10. J. J. Yang, D. Yu, Y. Takata, et al., "Dietary Fat Intake and Lung Cancer Risk: A Pooled Analysis," *Journal of Clinical Oncology* 35, no. 26 (2017): 3055–3064, [https://doi.org/10.1200/JCO.2017.73.3329.](https://doi.org/10.1200/JCO.2017.73.3329)

11. S. Burgess, G. Davey Smith, N. M. Davies, et al., "Guidelines for Performing Mendelian Randomization Investigations: Update for Summer 2023," *Wellcome Open Research* 4 (2019): 186, [https://doi.org/10.12688/](https://doi.org/10.12688/wellcomeopenres.15555.3) [wellcomeopenres.15555.3](https://doi.org/10.12688/wellcomeopenres.15555.3).

12. M. Xu, Y. Wang, R. Xia, Y. Wei, and X. Wei, "Role of the CCL2-CCR2 Signalling Axis in Cancer: Mechanisms and Therapeutic Targeting," *Cell Proliferation* 54, no. 10 (2021): e13115, [https://doi.org/10.1111/cpr.](https://doi.org/10.1111/cpr.13115) [13115.](https://doi.org/10.1111/cpr.13115)

13. M. Gerber, "Background Review Paper on Total Fat, Fatty Acid Intake and Cancers," *Annals of Nutrition & Metabolism* 55, no. 1–3 (2009): 140–161, <https://doi.org/10.1159/000229000>.

14. Y. F. Zhang, J. Lu, F. F. Yu, H. F. Gao, and Y. H. Zhou, "Polyunsaturated Fatty Acid Intake and Risk of Lung Cancer: A Meta-Analysis of Prospective Studies," *PLoS ONE* 9, no. 6 (2014): e99637, [https://doi.org/](https://doi.org/10.1371/journal.pone.0099637) [10.1371/journal.pone.0099637](https://doi.org/10.1371/journal.pone.0099637).

15. H. N. Luu, H. Cai, H. J. Murff, et al., "A Prospective Study of Dietary Polyunsaturated Fatty Acids Intake and Lung Cancer Risk," *International Journal of Cancer* 143, no. 9 (2018): 2225–2237, [https://doi.org/10.](https://doi.org/10.1002/ijc.31608) [1002/ijc.31608.](https://doi.org/10.1002/ijc.31608)

16. M. Kojima, K. Wakai, S. Tokudome, et al., "Serum Levels of Polyunsaturated Fatty Acids and Risk of Colorectal Cancer: A Prospective Study," *American Journal of Epidemiology* 161, no. 5 (2005): 462–471, <https://doi.org/10.1093/aje/kwi066>.

17. C. Pouchieu, V. Chajès, F. Laporte, et al., "Prospective Associations Between Plasma Saturated, Monounsaturated and Polyunsaturated Fatty Acids and Overall and Breast Cancer Risk—Modulation by Antioxidants: A Nested Case-Control Study," *PLoS ONE* 9, no. 2 (2014): e90442, <https://doi.org/10.1371/journal.pone.0090442>.

18. V. Chajès, V. Joulin, and F. Clavel-Chapelon, "The Fatty Acid Desaturation Index of Blood Lipids, as a Biomarker of Hepatic Stearoyl-CoA Desaturase Expression, Is a Predictive Factor of Breast Cancer Risk," *Current Opinion in Lipidology* 22, no. 1 (2011): 6–10, [https://doi.org/10.](https://doi.org/10.1097/MOL.0b013e3283404552) [1097/MOL.0b013e3283404552](https://doi.org/10.1097/MOL.0b013e3283404552).

19. J. Huang, X. X. Fan, J. He, et al., "SCD1 Is Associated With Tumor Promotion, Late Stage and Poor Survival in Lung Adenocarcinoma," *Oncotarget* 7, no. 26 (2016): 39970–39979, [https://doi.org/10.18632/oncot](https://doi.org/10.18632/oncotarget.9461) [arget.9461.](https://doi.org/10.18632/oncotarget.9461)

20. D. Hess, J. W. Chisholm, and R. A. Igal, "Inhibition of stearoylCoA Desaturase Activity Blocks Cell Cycle Progression and Induces Programmed Cell Death in Lung Cancer Cells," *PLoS ONE* 5, no. 6 (2010): e11394, [https://doi.org/10.1371/journal.pone.0011394.](https://doi.org/10.1371/journal.pone.0011394)

21. S. Doll, B. Proneth, Y. Y. Tyurina, et al., "ACSL4 Dictates Ferroptosis Sensitivity by Shaping Cellular Lipid Composition," *Nature Chemical Biology* 13, no. 1 (2017): 91–98,<https://doi.org/10.1038/nchembio.2239>.

22. Q. Zou, B. Tang, X. Chen, C. Zhang, and Y. Huang, "STK11 (LKB1) Mutation Suppresses Ferroptosis in Lung Adenocarcinoma by Facilitating Monounsaturated Fatty Acid Synthesis," *Open Medicine (Wars)* 19, no. 1 (2024): 20230845, [https://doi.org/10.1515/med-2023-0845.](https://doi.org/10.1515/med-2023-0845)

23. J. Dong, F. Qi, H. Qie, et al., "Oleic Acid Inhibits SDC4 and Promotes Ferroptosis in Lung Cancer Through GPX4/ACSL4," *Clinical Respiratory Journal* 18, no. 10 (2024): e70014, <https://doi.org/10.1111/crj.70014>.

24. J. Zhang, F. Song, X. Zhao, et al., "EGFR Modulates Monounsaturated Fatty Acid Synthesis Through Phosphorylation of SCD1 in Lung Cancer," *Molecular Cancer* 16, no. 1 (2017): 127, [https://doi.org/10.1186/](https://doi.org/10.1186/s12943-017-0704-x) [s12943-017-0704-x](https://doi.org/10.1186/s12943-017-0704-x).

25. Cole-Skinner B, Andre NM, Blankenheim Z, Root K, Simmons GE, Jr. Unsaturated Fatty Acid Alters the Immune Response in Non-Small Cell Lung Adenocarcinoma Through Regulation of HMGB1 Trafficking. bioRxiv 2023[,https://doi.org/10.1101/2023.11.08.566231](https://doi.org/10.1101/2023.11.08.566231).